Precision Biosciences INC 8-K filings

Precision BioSciences announced positive first quarter 2024 financial results, highlighted by increased revenue and progress in their gene editing programs, extending their cash runway into the second half of 2026.

Precision BioSciences has secured $300,000 through a private placement of shares to its management team at a premium to the market price.

Precision BioSciences has regained control of three gene editing programs after Prevail Therapeutics terminated their collaboration agreement, while also reporting a cash balance of approximately $137 million as of March 31, 2024.

Precision BioSciences announced its fourth quarter and full year 2023 financial results, highlighting progress in its in vivo gene editing programs and strategic financial moves.

Precision BioSciences has announced a public offering to sell 2.5 million shares of common stock and accompanying warrants, aiming to raise $40 million before expenses.

Precision BioSciences has executed a 1-for-30 reverse stock split of its common stock, effective February 13, 2024, to comply with Nasdaq's minimum bid price requirement.

Precision BioSciences has entered into new employment agreements with its top executives, including the CEO, CFO, General Counsel, and Chief Research Officer, reflecting updated compensation and severance terms.

Precision BioSciences' stockholders have approved a reverse stock split proposal and an adjournment proposal at a special meeting held on January 18, 2024.

Precision BioSciences has granted TG Therapeutics an exclusive license to develop and commercialize its allogeneic CAR T therapy, azer-cel, for non-oncological applications, receiving $17.5 million upfront and near-term payments and potentially up to $288 million in milestone payments.